Free tool
FAERS Monitor: Sernivo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208079 or its brand name (Sernivo, Betamethasone Dipropionate). Reports on generic versions are filed under their own applications.
Reports
6,091
Serious
4,072
67% of reports
Hospitalization
1,820
Death reported
503
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,453
- off label use672
- macular degeneration532
- nausea501
- psoriasis473
- pruritus468
- pain451
- condition aggravated429
- headache394
- pain in extremity392
- rash387
- fatigue381
- product use in unapproved indication348
- dyspnoea341
- therapeutic product effect incomplete328
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 25 |
| 2006 | 18 |
| 2007 | 24 |
| 2008 | 22 |
| 2009 | 21 |
| 2010 | 16 |
| 2011 | 41 |
| 2012 | 50 |
| 2013 | 38 |
| 2014 | 48 |
| 2015 | 87 |
| 2016 | 167 |
| 2017 | 222 |
| 2018 | 246 |
| 2019 | 354 |
| 2020 | 433 |
| 2021 | 743 |
| 2022 | 738 |
| 2023 | 780 |
| 2024 | 651 |
| 2025 | 756 |
| 2026 | 594 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 532 | 160.9 | 148.1 | 80,681 |
| therapeutic product effect incompleteSignal | 328 | 16.0 | 14.4 | 4,589 |
| psoriasisSignal | 473 | 12.5 | 11.5 | 5,028 |
| condition aggravatedSignal | 429 | 4.9 | 4.5 | 1,336 |
| product use in unapproved indicationSignal | 348 | 4.9 | 4.4 | 1,072 |
| pain in extremitySignal | 392 | 4.6 | 4.2 | 1,115 |
| pruritusSignal | 468 | 4.2 | 3.9 | 1,162 |
| drug ineffectiveSignal | 1,453 | 3.8 | 3.6 | 3,206 |
| rashSignal | 387 | 3.1 | 2.8 | 548 |
| off label useSignal | 672 | 2.7 | 2.5 | 719 |
| painSignal | 451 | 2.5 | 2.3 | 430 |
| nauseaSignal | 501 | 2.2 | 2.0 | 334 |
| headacheSignal | 394 | 2.2 | 2.0 | 255 |
| dyspnoeaSignal | 341 | 2.1 | 1.9 | 195 |
| fatigue | 381 | 1.7 | 1.5 | 111 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.